ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2221

Reduction of Ovarian Reserve in Adult Patients with Dermatomyositis

Fernando Henrique Carlos de Souza1, Samuel Katsuyuki Shinjo1, Lucas Yugo Shiguehara Yamakami2, Vilma dos Santos Trindade Viana1, Edmund Chada Baracat3, Eloisa Bonfa4 and Clovis Artur Almeida Silva5, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Gynecology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Gynecology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 5Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: dermatomyositis, Fertility, hormones, inflammatory myositis and ovarian

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Dermatomyositis (DM) affects female gender during reproductive age, in which ovarian reserve and future fertility are major topics of interest. However, there is no systematic study assessing these abnormalities in patients with DM. Therefore, the aim of the present study was to evaluate ovarian reserve markers and anti-corpus luteum (anti-CoL) antibodies in patients with DM.

Methods: All 40 female patients with DM (Bohan e Peter criteria, 1975), aged between 18 and 42 years, followed at our tertiary center, from March 2011 to December 2012, were invited to participate. Exclusion criteria were hormonal contraceptive use in the last six months (n=13), neoplasia (n=3), overlap systemic autoimmune diseases (n=3), pregnancy (n=2), gynecological surgery (n=1) and did not agree to participate (n=2). The remaining sixteen DM patients and 23 healthy controls were evaluated at early follicular phase of menstrual cycle. IgG anti-CoL (immunoblotting), follicle stimulating hormone (FSH), estradiol, inhibin B, anti-Müllerian hormone (AMH) serum levels (ELISA) and sonographic antral follicle count (AFC) were determined.

Results: DM patients and controls had comparable mean age (33.4±6.8 vs. 31.4±6.8 years, P=0.337), ethnicity and socioeconomic class (P>0.05). DM mean age of onset was 29.1±4.7 years and disease duration of 5.6±3.2 years. Comorbidities and life style were similar in both groups (P>0.05). Menstrual cycles were alike in both groups with a similar frequency of age at menarche, gynecological age, duration and length of menstrual cycle (P>0.05). Of note, AMH ≤ 1 ng/mL (50% vs. 13%, P=0.027) and number of the AFC (10.5±5.6 vs. 17.3±0.7, P=0.017) were significantly reduced in DM patients compared to controls. Serum FSH (6.2±2.0 vs. 6.6±3.8 IU/L, P=0.617) and inhibin B levels (49.8±31.5 vs. 45.2±29.0 ng/mL, P=0.616) were comparable to controls whereas serum estradiol level [45.0 (29-126) vs. 34 (24-128) pg/mL, P<0.001] was higher in DM patients. Ovarian volumes [6.2 (4.7-8.2) vs. 5.5 (1.4-15.8) mm3, P=0.214], and the frequency of anti-CoL antibody (6.5% vs. 0%, P=0.398) were also alike in both groups (P>0.05).

Conclusion: The present study was the first to identify that patients with DM may have a shortened reproductive lifespan. Further studies are necessary to assess the possible role of disease and treatment related factors underlying ovarian impairment in these patients.


Disclosure:

F. H. C. de Souza,
None;

S. K. Shinjo,
None;

L. Y. S. Yamakami,
None;

V. D. S. T. Viana,
None;

E. C. Baracat,
None;

E. Bonfa,
None;

C. A. A. Silva,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-of-ovarian-reserve-in-adult-patients-with-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology